AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] The Wendy's Company Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Amendment No. 7 to Schedule 13D, filed on 20 June 2025, details the current and potential equity position of Ryan Schulke in Fluent, Inc. (NASDAQ: FLNT). Schulke now beneficially owns 4,934,295 common shares, equal to 21.1 % of the 21,853,756 shares outstanding as of 18 June 2025. His holdings comprise directly owned stock, multiple family trusts, a GRAT structure, and 333,334 shares held through RSMC Partners, LLC.

The filing highlights three key instruments that could materially expand ownership:

  • Pre-Funded Warrants: 1,041,123 total warrants (551,977 to Schulke, 489,146 to a family trust) purchased on 2 Dec 2024 and 19 Mar 2025. They are exercisable at $0.0005 per share and became exercisable following shareholder approval at the 18 June 2025 annual meeting.
  • Convertible Subordinated Note: Issued 19 Aug 2024, currently convertible into 459,082 shares at the lesser of $3.01 or a market-linked formula, with a $1.00 floor.
  • Stockholdersâ€� Agreement with Dr. Phillip Frost / Frost Gamma: Provides Schulke shared voting alignment over an additional 6,787,063 shares.

If the warrants are fully exercised and the note converted—and if Frost-related shares are counted—Schulke’s aggregate influence could reach 11,271,358 shares, or 48.1 % of the company, potentially giving him effective control of board appointments. All purchases were funded with Schulke’s personal funds, and the filing notes no additional plans regarding mergers, asset sales or other transformative actions.

L'Emendamento n. 7 al Schedule 13D, depositato il 20 giugno 2025, descrive la posizione azionaria attuale e potenziale di Ryan Schulke in Fluent, Inc. (NASDAQ: FLNT). Schulke attualmente possiede beneficiariamente 4.934.295 azioni ordinarie, pari al 21,1% delle 21.853.756 azioni in circolazione al 18 giugno 2025. Le sue partecipazioni comprendono azioni detenute direttamente, diversi trust familiari, una struttura GRAT e 333.334 azioni detenute tramite RSMC Partners, LLC.

Il documento evidenzia tre strumenti chiave che potrebbero ampliare significativamente la proprietà:

  • Warrant Pre-Finanziati: un totale di 1.041.123 warrant (551.977 a Schulke, 489.146 a un trust familiare) acquistati il 2 dicembre 2024 e il 19 marzo 2025. Sono esercitabili a $0,0005 per azione e sono diventati esercitabili dopo l'approvazione degli azionisti durante l'assemblea annuale del 18 giugno 2025.
  • Nota Subordinata Convertibile: emessa il 19 agosto 2024, attualmente convertibile in 459.082 azioni al prezzo minore tra $3,01 o una formula legata al mercato, con un prezzo minimo di $1,00.
  • Accordo tra Azionisti con il Dr. Phillip Frost / Frost Gamma: garantisce a Schulke un allineamento di voto condiviso su ulteriori 6.787.063 azioni.

Se i warrant venissero esercitati completamente e la nota convertita—e se si considerassero anche le azioni legate a Frost—l'influenza complessiva di Schulke potrebbe raggiungere 11.271.358 azioni, pari al 48,1% della società, potenzialmente conferendogli il controllo effettivo sulle nomine del consiglio di amministrazione. Tutti gli acquisti sono stati finanziati con fondi personali di Schulke e il documento non segnala ulteriori piani riguardo fusioni, vendite di asset o altre azioni trasformative.

La Enmienda n.º 7 al Schedule 13D, presentada el 20 de junio de 2025, detalla la posición accionaria actual y potencial de Ryan Schulke en Fluent, Inc. (NASDAQ: FLNT). Schulke ahora posee beneficiosamente 4.934.295 acciones comunes, equivalentes al 21,1 % de las 21.853.756 acciones en circulación al 18 de junio de 2025. Sus participaciones incluyen acciones de propiedad directa, varios fideicomisos familiares, una estructura GRAT y 333.334 acciones mantenidas a través de RSMC Partners, LLC.

El documento destaca tres instrumentos clave que podrían ampliar materialmente la propiedad:

  • Warrants Pre-Financiados: un total de 1.041.123 warrants (551.977 para Schulke, 489.146 para un fideicomiso familiar) comprados el 2 de diciembre de 2024 y el 19 de marzo de 2025. Son ejercitables a $0,0005 por acción y se volvieron ejercitables tras la aprobación de los accionistas en la reunión anual del 18 de junio de 2025.
  • Nota Subordinada Convertible: emitida el 19 de agosto de 2024, actualmente convertible en 459.082 acciones al menor precio entre $3,01 o una fórmula vinculada al mercado, con un piso de $1,00.
  • Acuerdo de Accionistas con el Dr. Phillip Frost / Frost Gamma: otorga a Schulke una alineación compartida de voto sobre otras 6.787.063 acciones.

Si los warrants se ejercen completamente y la nota se convierte—y si se cuentan las acciones relacionadas con Frost—la influencia agregada de Schulke podría alcanzar 11.271.358 acciones, o el 48,1 % de la compañía, dándole potencialmente el control efectivo sobre los nombramientos del consejo. Todas las compras fueron financiadas con fondos personales de Schulke, y el documento no menciona planes adicionales relacionados con fusiones, ventas de activos u otras acciones transformadoras.

2025ë…� 6ì›� 20ì� 제출ë� Schedule 13Dì� 수정ì•� 7호는 Fluent, Inc. (NASDAQ: FLNT)ì—서 ë¼ì´ì–� ìŠì¼€(Ryan Schulke)ì� 현재 ë°� 잠재ì � ì§€ë¶� ìƒí™©ì� ìƒì„¸íž� 설명합니ë‹�. ìŠì¼€ëŠ� 현재 2025ë…� 6ì›� 18ì� 기준 ì´� 21,853,756ì£� ì¤� 21.1%ì—� 해당하는 4,934,295ì£¼ì˜ ë³´í†µì£¼ë¥¼ 실질ì ìœ¼ë¡� 소유하고 있습니다. ê·¸ì˜ ë³´ìœ  ì§€ë¶„ì€ ì§ì ‘ 보유 주ì‹, 여러 ê°€ì¡� ì‹ íƒ, GRAT 구조, 그리ê³� RSMC Partners, LLCë¥� 통한 333,334주로 구성ë©ë‹ˆë‹�.

ì� 문서ëŠ� ì†Œìœ ê¶Œì„ í¬ê²Œ 확대í•� ìˆ� 있는 ì„� 가지 주요 수단ì� 강조합니ë‹�:

  • ì„ ë‚© 워런íŠ�(Pre-Funded Warrants): ì´� 1,041,123ê°œì˜ ì›ŒëŸ°íŠ�(ìŠì¼€ 551,977ì£�, ê°€ì¡� ì‹ íƒ 489,146ì£�)ê°€ 2024ë…� 12ì›� 2ì¼ê³¼ 2025ë…� 3ì›� 19ì¼ì— 구입ë˜ì—ˆìŠµë‹ˆë‹�. 주당 행사 ê°€ê²©ì€ $0.0005ì´ë©°, 2025ë…� 6ì›� 18ì� 정기 주주ì´íšŒì—서 주주 ìŠ¹ì¸ í›� 행사 가능해졌습니다.
  • 전환 후순ìœ� 채권(Convertible Subordinated Note): 2024ë…� 8ì›� 19ì� 발행ë˜ì—ˆìœ¼ë©°, 현재 $3.01 ë˜ëŠ” 시장 ì—°ë™ ê³µì‹ ì¤� ë‚®ì€ ê°€ê²©ì— 459,082주로 전환 가능하ë©�, 최저 ê°€ê²©ì€ $1.00입니ë‹�.
  • Dr. Phillip Frost / Frost Gamma와ì� 주주 협약: ìŠì¼€ê°€ 추가ë¡� 6,787,063ì£¼ì— ëŒ€í•� ê³µë™ íˆ¬í‘œ 권한ì� ê°€ì§� ìˆ� 있ë„ë¡� 합니ë‹�.

만약 워런트를 ì „ë¶€ 행사하고 채권ì� 전환하며 Frost ê´€ë � 주ì‹ì� í¬í•¨í•œë‹¤ë©�, ìŠì¼€ì� ì´� ì˜í–¥ë ¥ì€ 11,271,358ì£�, ì¦� 회사 ì§€ë¶„ì˜ 48.1%ì—� 달할 ìˆ� 있으ë©�, ì´ë¡œì� ì´ì‚¬íš� 임명ì—� 대í•� 실질ì � í†µì œê¶Œì„ ê°€ì§� 가능성ì� 있습니다. 모든 ë§¤ìž…ì€ ìŠì¼€ ê°œì¸ ìžê¸ˆìœ¼ë¡œ ì´ë£¨ì–´ì¡Œìœ¼ë©°, 해당 문서ì—는 합병, ìžì‚° ë§¤ê° ë˜ëŠ” 기타 ë³€í˜ì  조치ì—� 대í•� 추가 계íšì€ 언급ë˜ì–´ 있지 않습니다.

L'amendement n° 7 au Schedule 13D, déposé le 20 juin 2025, détaille la position actuelle et potentielle en actions de Ryan Schulke dans Fluent, Inc. (NASDAQ : FLNT). Schulke détient désormais 4 934 295 actions ordinaires en propriété bénéficiaire, soit 21,1 % des 21 853 756 actions en circulation au 18 juin 2025. Ses avoirs comprennent des actions détenues directement, plusieurs trusts familiaux, une structure GRAT, ainsi que 333 334 actions détenues via RSMC Partners, LLC.

Le dépôt met en lumière trois instruments clés susceptibles d'élargir significativement sa participation :

  • Warrants préfinancés : au total 1 041 123 warrants (551 977 pour Schulke, 489 146 pour un trust familial) acquis les 2 décembre 2024 et 19 mars 2025. Ils sont exerçables à 0,0005 $ par action et sont devenus exerçables après l'approbation des actionnaires lors de l'assemblée générale annuelle du 18 juin 2025.
  • Billet subordonné convertible : émis le 19 août 2024, actuellement convertible en 459 082 actions au plus bas entre 3,01 $ ou une formule liée au marché, avec un plancher à 1,00 $.
  • Accord d'actionnaires avec le Dr Phillip Frost / Frost Gamma : offre à Schulke un alignement de vote partagé sur 6 787 063 actions supplémentaires.

Si les warrants sont exercés en totalité et la note convertie � et si les actions liées à Frost sont prises en compte � l'influence globale de Schulke pourrait atteindre 11 271 358 actions, soit 48,1 % de la société, lui donnant potentiellement le contrôle effectif des nominations au conseil d'administration. Tous les achats ont été financés avec les fonds personnels de Schulke, et le dépôt ne mentionne aucun plan supplémentaire concernant des fusions, ventes d'actifs ou autres actions transformantes.

Nachtrag Nr. 7 zum Schedule 13D, eingereicht am 20. Juni 2025, beschreibt die aktuelle und potenzielle Aktienposition von Ryan Schulke bei Fluent, Inc. (NASDAQ: FLNT). Schulke besitzt nun wirtschaftlich 4.934.295 Stammaktien, was 21,1 % der 21.853.756 ausstehenden Aktien zum 18. Juni 2025 entspricht. Sein Bestand umfasst direkt gehaltene Aktien, mehrere Familienstiftungen, eine GRAT-Struktur sowie 333.334 Aktien, die über RSMC Partners, LLC gehalten werden.

Die Einreichung hebt drei wesentliche Instrumente hervor, die das Eigentum erheblich erweitern könnten:

  • Vorfinanzierte Warrants: Insgesamt 1.041.123 Warrants (551.977 an Schulke, 489.146 an einen Familienstift) wurden am 2. Dezember 2024 und 19. März 2025 erworben. Sie sind zu einem Ausübungspreis von 0,0005 $ pro Aktie ausübbar und wurden nach der Zustimmung der Aktionäre auf der Jahreshauptversammlung am 18. Juni 2025 ausübbar.
  • Wandelbare nachrangige Schuldverschreibung: Ausgegeben am 19. August 2024, derzeit wandelbar in 459.082 Aktien zum niedrigeren Preis von 3,01 $ oder einer marktgebundenen Formel, mit einem Mindestpreis von 1,00 $.
  • Aktionärsvereinbarung mit Dr. Phillip Frost / Frost Gamma: Gewährt Schulke eine gemeinsame Stimmrechtsausrichtung über zusätzliche 6.787.063 Aktien.

Wenn die Warrants vollständig ausgeübt und die Schuldverschreibung gewandelt wird � und wenn die Frost-bezogenen Aktien mitgezählt werden � könnte Schulkes gesamter Einfluss 11.271.358 Aktien oder 48,1 % des Unternehmens erreichen, was ihm potenziell die effektive Kontrolle über die Vorstandsernennungen verschafft. Alle Käufe wurden mit Schulkes persönlichen Mitteln finanziert, und die Einreichung vermerkt keine weiteren Pläne bezüglich Fusionen, Vermögensverkäufen oder anderen transformativen Maßnahmen.

Positive
  • High insider commitment: Schulke’s 21.1 % stake signals confidence in FLNT’s prospects.
  • Personal funds used: No company cash outflow; purchase funded privately.
  • Board support alignment: Voting agreement with Frost could provide stable leadership direction.
Negative
  • Dilution risk: Exercising 1.04 M pre-funded warrants and converting notes will expand share count and may pressure valuation.
  • Control concentration: Potential 48 % influence could marginalize minority shareholders.
  • Variable conversion price: Note converts at the lower of $3.01 or market price (floor $1.00), incentivising conversion during price weakness.

Insights

TL;DR: Insider boosts stake to 21.1 %; cheap warrants and note could nearly double float, creating dilution but signalling commitment.

Schulke’s position confirms deep insider alignment in FLNT. The $0.0005 exercise price makes the warrants economically risk-free, meaning conversion is almost certain and will expand shares outstanding by roughly 4.8 %. The note’s market-based conversion could add further supply during price weakness. While insider confidence can reassure investors, the potential 48 % fully-diluted control raises concentration and liquidity concerns. Short- to mid-term, headline impact is moderate; material dilution will depend on the timing of conversions.

TL;DR: Voting pact with Frost plus warrants positions Schulke near de-facto control; board influence increases, minority rights need monitoring.

The filing reveals a structured path to majority influence without launching a formal takeover. By aligning with Frost Gamma, Schulke can effectively command almost half of outstanding shares. This heightens key-man risk and may deter hostile activity, but also raises governance scrutiny regarding minority shareholder protections, related-party transactions, and future capital raises. Exercise of warrants at a nominal price transfers value from existing holders to Schulke/trusts. Impact is strategically significant yet not immediately disruptive, justifying a neutral rating with a watch on future actions.

L'Emendamento n. 7 al Schedule 13D, depositato il 20 giugno 2025, descrive la posizione azionaria attuale e potenziale di Ryan Schulke in Fluent, Inc. (NASDAQ: FLNT). Schulke attualmente possiede beneficiariamente 4.934.295 azioni ordinarie, pari al 21,1% delle 21.853.756 azioni in circolazione al 18 giugno 2025. Le sue partecipazioni comprendono azioni detenute direttamente, diversi trust familiari, una struttura GRAT e 333.334 azioni detenute tramite RSMC Partners, LLC.

Il documento evidenzia tre strumenti chiave che potrebbero ampliare significativamente la proprietà:

  • Warrant Pre-Finanziati: un totale di 1.041.123 warrant (551.977 a Schulke, 489.146 a un trust familiare) acquistati il 2 dicembre 2024 e il 19 marzo 2025. Sono esercitabili a $0,0005 per azione e sono diventati esercitabili dopo l'approvazione degli azionisti durante l'assemblea annuale del 18 giugno 2025.
  • Nota Subordinata Convertibile: emessa il 19 agosto 2024, attualmente convertibile in 459.082 azioni al prezzo minore tra $3,01 o una formula legata al mercato, con un prezzo minimo di $1,00.
  • Accordo tra Azionisti con il Dr. Phillip Frost / Frost Gamma: garantisce a Schulke un allineamento di voto condiviso su ulteriori 6.787.063 azioni.

Se i warrant venissero esercitati completamente e la nota convertita—e se si considerassero anche le azioni legate a Frost—l'influenza complessiva di Schulke potrebbe raggiungere 11.271.358 azioni, pari al 48,1% della società, potenzialmente conferendogli il controllo effettivo sulle nomine del consiglio di amministrazione. Tutti gli acquisti sono stati finanziati con fondi personali di Schulke e il documento non segnala ulteriori piani riguardo fusioni, vendite di asset o altre azioni trasformative.

La Enmienda n.º 7 al Schedule 13D, presentada el 20 de junio de 2025, detalla la posición accionaria actual y potencial de Ryan Schulke en Fluent, Inc. (NASDAQ: FLNT). Schulke ahora posee beneficiosamente 4.934.295 acciones comunes, equivalentes al 21,1 % de las 21.853.756 acciones en circulación al 18 de junio de 2025. Sus participaciones incluyen acciones de propiedad directa, varios fideicomisos familiares, una estructura GRAT y 333.334 acciones mantenidas a través de RSMC Partners, LLC.

El documento destaca tres instrumentos clave que podrían ampliar materialmente la propiedad:

  • Warrants Pre-Financiados: un total de 1.041.123 warrants (551.977 para Schulke, 489.146 para un fideicomiso familiar) comprados el 2 de diciembre de 2024 y el 19 de marzo de 2025. Son ejercitables a $0,0005 por acción y se volvieron ejercitables tras la aprobación de los accionistas en la reunión anual del 18 de junio de 2025.
  • Nota Subordinada Convertible: emitida el 19 de agosto de 2024, actualmente convertible en 459.082 acciones al menor precio entre $3,01 o una fórmula vinculada al mercado, con un piso de $1,00.
  • Acuerdo de Accionistas con el Dr. Phillip Frost / Frost Gamma: otorga a Schulke una alineación compartida de voto sobre otras 6.787.063 acciones.

Si los warrants se ejercen completamente y la nota se convierte—y si se cuentan las acciones relacionadas con Frost—la influencia agregada de Schulke podría alcanzar 11.271.358 acciones, o el 48,1 % de la compañía, dándole potencialmente el control efectivo sobre los nombramientos del consejo. Todas las compras fueron financiadas con fondos personales de Schulke, y el documento no menciona planes adicionales relacionados con fusiones, ventas de activos u otras acciones transformadoras.

2025ë…� 6ì›� 20ì� 제출ë� Schedule 13Dì� 수정ì•� 7호는 Fluent, Inc. (NASDAQ: FLNT)ì—서 ë¼ì´ì–� ìŠì¼€(Ryan Schulke)ì� 현재 ë°� 잠재ì � ì§€ë¶� ìƒí™©ì� ìƒì„¸íž� 설명합니ë‹�. ìŠì¼€ëŠ� 현재 2025ë…� 6ì›� 18ì� 기준 ì´� 21,853,756ì£� ì¤� 21.1%ì—� 해당하는 4,934,295ì£¼ì˜ ë³´í†µì£¼ë¥¼ 실질ì ìœ¼ë¡� 소유하고 있습니다. ê·¸ì˜ ë³´ìœ  ì§€ë¶„ì€ ì§ì ‘ 보유 주ì‹, 여러 ê°€ì¡� ì‹ íƒ, GRAT 구조, 그리ê³� RSMC Partners, LLCë¥� 통한 333,334주로 구성ë©ë‹ˆë‹�.

ì� 문서ëŠ� ì†Œìœ ê¶Œì„ í¬ê²Œ 확대í•� ìˆ� 있는 ì„� 가지 주요 수단ì� 강조합니ë‹�:

  • ì„ ë‚© 워런íŠ�(Pre-Funded Warrants): ì´� 1,041,123ê°œì˜ ì›ŒëŸ°íŠ�(ìŠì¼€ 551,977ì£�, ê°€ì¡� ì‹ íƒ 489,146ì£�)ê°€ 2024ë…� 12ì›� 2ì¼ê³¼ 2025ë…� 3ì›� 19ì¼ì— 구입ë˜ì—ˆìŠµë‹ˆë‹�. 주당 행사 ê°€ê²©ì€ $0.0005ì´ë©°, 2025ë…� 6ì›� 18ì� 정기 주주ì´íšŒì—서 주주 ìŠ¹ì¸ í›� 행사 가능해졌습니다.
  • 전환 후순ìœ� 채권(Convertible Subordinated Note): 2024ë…� 8ì›� 19ì� 발행ë˜ì—ˆìœ¼ë©°, 현재 $3.01 ë˜ëŠ” 시장 ì—°ë™ ê³µì‹ ì¤� ë‚®ì€ ê°€ê²©ì— 459,082주로 전환 가능하ë©�, 최저 ê°€ê²©ì€ $1.00입니ë‹�.
  • Dr. Phillip Frost / Frost Gamma와ì� 주주 협약: ìŠì¼€ê°€ 추가ë¡� 6,787,063ì£¼ì— ëŒ€í•� ê³µë™ íˆ¬í‘œ 권한ì� ê°€ì§� ìˆ� 있ë„ë¡� 합니ë‹�.

만약 워런트를 ì „ë¶€ 행사하고 채권ì� 전환하며 Frost ê´€ë � 주ì‹ì� í¬í•¨í•œë‹¤ë©�, ìŠì¼€ì� ì´� ì˜í–¥ë ¥ì€ 11,271,358ì£�, ì¦� 회사 ì§€ë¶„ì˜ 48.1%ì—� 달할 ìˆ� 있으ë©�, ì´ë¡œì� ì´ì‚¬íš� 임명ì—� 대í•� 실질ì � í†µì œê¶Œì„ ê°€ì§� 가능성ì� 있습니다. 모든 ë§¤ìž…ì€ ìŠì¼€ ê°œì¸ ìžê¸ˆìœ¼ë¡œ ì´ë£¨ì–´ì¡Œìœ¼ë©°, 해당 문서ì—는 합병, ìžì‚° ë§¤ê° ë˜ëŠ” 기타 ë³€í˜ì  조치ì—� 대í•� 추가 계íšì€ 언급ë˜ì–´ 있지 않습니다.

L'amendement n° 7 au Schedule 13D, déposé le 20 juin 2025, détaille la position actuelle et potentielle en actions de Ryan Schulke dans Fluent, Inc. (NASDAQ : FLNT). Schulke détient désormais 4 934 295 actions ordinaires en propriété bénéficiaire, soit 21,1 % des 21 853 756 actions en circulation au 18 juin 2025. Ses avoirs comprennent des actions détenues directement, plusieurs trusts familiaux, une structure GRAT, ainsi que 333 334 actions détenues via RSMC Partners, LLC.

Le dépôt met en lumière trois instruments clés susceptibles d'élargir significativement sa participation :

  • Warrants préfinancés : au total 1 041 123 warrants (551 977 pour Schulke, 489 146 pour un trust familial) acquis les 2 décembre 2024 et 19 mars 2025. Ils sont exerçables à 0,0005 $ par action et sont devenus exerçables après l'approbation des actionnaires lors de l'assemblée générale annuelle du 18 juin 2025.
  • Billet subordonné convertible : émis le 19 août 2024, actuellement convertible en 459 082 actions au plus bas entre 3,01 $ ou une formule liée au marché, avec un plancher à 1,00 $.
  • Accord d'actionnaires avec le Dr Phillip Frost / Frost Gamma : offre à Schulke un alignement de vote partagé sur 6 787 063 actions supplémentaires.

Si les warrants sont exercés en totalité et la note convertie � et si les actions liées à Frost sont prises en compte � l'influence globale de Schulke pourrait atteindre 11 271 358 actions, soit 48,1 % de la société, lui donnant potentiellement le contrôle effectif des nominations au conseil d'administration. Tous les achats ont été financés avec les fonds personnels de Schulke, et le dépôt ne mentionne aucun plan supplémentaire concernant des fusions, ventes d'actifs ou autres actions transformantes.

Nachtrag Nr. 7 zum Schedule 13D, eingereicht am 20. Juni 2025, beschreibt die aktuelle und potenzielle Aktienposition von Ryan Schulke bei Fluent, Inc. (NASDAQ: FLNT). Schulke besitzt nun wirtschaftlich 4.934.295 Stammaktien, was 21,1 % der 21.853.756 ausstehenden Aktien zum 18. Juni 2025 entspricht. Sein Bestand umfasst direkt gehaltene Aktien, mehrere Familienstiftungen, eine GRAT-Struktur sowie 333.334 Aktien, die über RSMC Partners, LLC gehalten werden.

Die Einreichung hebt drei wesentliche Instrumente hervor, die das Eigentum erheblich erweitern könnten:

  • Vorfinanzierte Warrants: Insgesamt 1.041.123 Warrants (551.977 an Schulke, 489.146 an einen Familienstift) wurden am 2. Dezember 2024 und 19. März 2025 erworben. Sie sind zu einem Ausübungspreis von 0,0005 $ pro Aktie ausübbar und wurden nach der Zustimmung der Aktionäre auf der Jahreshauptversammlung am 18. Juni 2025 ausübbar.
  • Wandelbare nachrangige Schuldverschreibung: Ausgegeben am 19. August 2024, derzeit wandelbar in 459.082 Aktien zum niedrigeren Preis von 3,01 $ oder einer marktgebundenen Formel, mit einem Mindestpreis von 1,00 $.
  • Aktionärsvereinbarung mit Dr. Phillip Frost / Frost Gamma: Gewährt Schulke eine gemeinsame Stimmrechtsausrichtung über zusätzliche 6.787.063 Aktien.

Wenn die Warrants vollständig ausgeübt und die Schuldverschreibung gewandelt wird � und wenn die Frost-bezogenen Aktien mitgezählt werden � könnte Schulkes gesamter Einfluss 11.271.358 Aktien oder 48,1 % des Unternehmens erreichen, was ihm potenziell die effektive Kontrolle über die Vorstandsernennungen verschafft. Alle Käufe wurden mit Schulkes persönlichen Mitteln finanziert, und die Einreichung vermerkt keine weiteren Pläne bezüglich Fusionen, Vermögensverkäufen oder anderen transformativen Maßnahmen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Radkoski Lindsay J.

(Last) (First) (Middle)
C/O THE WENDY'S COMPANY
ONE DAVE THOMAS BLVD.

(Street)
DUBLIN OH 43017

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Wendy's Co [ WEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CMO, U.S.
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units(1) (2) 06/16/2025 A 60(3) (4) (4) Common Stock 60 $0 55,566 D
Restricted Stock Units(1) (2) 06/16/2025 A 15(3) (5) (5) Common Stock 15 $0 55,581 D
Restricted Stock Units(1) (2) 06/16/2025 A 105(3) (6) (6) Common Stock 105 $0 55,686 D
Restricted Stock Units(1) (2) 06/16/2025 A 38(3) (7) (7) Common Stock 38 $0 55,724 D
Restricted Stock Units(1) (2) 06/16/2025 A 95(3) (8) (8) Common Stock 95 $0 55,819 D
Restricted Stock Units(1) (2) 06/16/2025 A 380(3) (9) (9) Common Stock 380 $0 56,199 D
Explanation of Responses:
1. With tandem dividend equivalent rights and tax withholding rights.
2. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
3. Represents dividend equivalent units issued on June 16, 2025.
4. The restricted stock units will vest in full on August 12, 2025, subject to Ms. Radkoski's continued employment with the Company on the vesting date.
5. The restricted stock units will vest in two remaining equal installments on August 11, 2025 and 2026, subject to Ms. Radkoski's continued employment with the Company on the applicable vesting date.
6. The restricted stock units will vest in full on December 7, 2026, subject to Ms. Radkoski's continued employment with the Company on the applicable vesting date.
7. The restricted stock units will vest in three equal installments on August 5, 2025, 2026 and 2027, subject to Ms. Radkoski's continued employment with the Company on the applicable vesting date.
8. The restricted stock units will vest in three equal installments on August 15, 2025, 2026 and 2027, subject to Ms. Radkoski's continued employment with the Company on the applicable vesting date.
9. The restricted stock units will vest in full on August 15, 2027, subject to Ms. Radkoski's continued employment with the Company on the vesting date.
/s/ Mark L. Johnson, Attorney-in-Fact 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Fluent (FLNT) shares does Ryan Schulke currently own?

He beneficially owns 4,934,295 shares, representing 21.1 % of outstanding stock.

What is the exercise price of the newly disclosed pre-funded warrants?

The warrants are exercisable at $0.0005 per share and terminate when fully exercised.

How could Schulke’s ownership in FLNT reach 48.1 %?

If all warrants and notes are converted and Frost/Gamma shares are counted via the voting pact, total influence would be 11,271,358 shares (48.1 %).

When did shareholders approve the issuance of the pre-funded warrants?

Approval was granted at the 18 June 2025 annual meeting.

What is the conversion formula for the August 2024 subordinated note?

Shares convert at the lesser of $3.01 or the greater of market closing bid and $1.00 on the conversion date.
Wendys Co

NASDAQ:WEN

WEN Rankings

WEN Latest News

WEN Latest SEC Filings

WEN Stock Data

2.24B
173.96M
9.14%
94.51%
8.42%
Restaurants
Retail-eating & Drinking Places
United States
DUBLIN